We included three samples from the estrogen receptor-positive (ER+) group, two from the human epidermal growth factor receptor 2 positive (HER2+) group, and three from the triple-negative breast cancer (TNBC) group, ensuring each had a cell count within the range of 1000–2000. Here, ERBB2 is linked to triple-negative breast carcinoma.